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Abstract: Our commentary of the article “‘Screening’ for Breast Cancer: Misguided Research Misinforming
Public Policies” has two main parts. First we address some of the methodological points raised by Professor
Miettinen. Then we review more specific aspects of the Swiss Medical Board statement on mammography
screening for early detection of breast cancer.
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Professor Miettinen presents his views on how one should assess the benefit of cancer screening and he
highlights a few difficulties. He considers, for example, well-known difficulties (Hernan, 2010) of the
incidence-density ratio (hazard ratio) of the cancer-related mortality as a useful metric for the benefit of
cancer screening. Even in randomized studies of screening versus no screening with perfect compliance, this
ratio is not constant over the follow-up time after having started screening. This phenomenon is clearly and
easily observable in screening trials in which only one screening is conducted in a lifetime – possibly in colon
cancer screening with sigmoidoscopy (Atkin et al., 2010) or colonoscopy. If the screening examination needs
to be repeated, more complications arise in using the incidence-density ratio as an efficacy metric.
Professor Miettinen proposes a new metric for determining whether to screen for cancer or not. He
states that almost all experts missed addressing the most crucial parameter (of Nature): “the risk/prob-
ability of death from the cancer as a function (causal) of its treatment (early vs. late) in a defined domain
(preclinical) of applying the compared diagnostic-therapeutic regimens”. So what the patient and the doctor
want to know is “the reduction in the cancer’s case-fatality rate resulting from its early treatments following
its early – latent-stage, preclinical – diagnoses in lieu of treatments of the cancer when it already is
clinically manifest.” He argues that most experts and others were inappropriately interpreting the results of
the conducted randomized screening trials. It is not clear whether he questions the conduct of these trials.
In order to simplify the arguments, let us review the situation in which a once only screening is
compared to no screening. As clearly highlighted by Professor Miettinen, the isolated screening examina-
tion per se has no effect, it is the screening as a starting point of a chain of procedures triggered by a result
possibly indicating further diagnostic investigation which might lead to a definite diagnosis followed by
treatment (which might subsequently be modified as judged necessary by some clinical experts). Therefore,
a randomized trial of screening versus no screening is actually assessing how – over a carefully defined
time horizon – results in the population without initial screening examination, differ from results in the
population which was screened and underwent this cascade of interventions. Any marginal differences
observed in cancer-specific mortality (or other outcomes such as cancer diagnoses and all-cause mortality)
after, for example 15 years, are the combined result of starting the cascade versus not starting the cascade.
Any attempt to disentangle the relative contribution of the separate steps is probably impossible. If
recruitment to the randomized screening trial happens over several years, then possibly some elements
of the steps in obtaining a definite diagnosis and what treatments are used might change over time and not
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all persons randomized to screening will be “exposed” to the same elements of the cascade. What will be
observed after – say – 15 years is a mixed effect averaged over screening plus the varying cascade elements
versus cascade elements in standard care in the no screening group. Even if recruitment time would be
short and cascade elements the same for those in the screening arm of the trial, the usually long follow-up
will lead to discussions about the final results of the trial. If some elements of the cascade have changed by
the time trial results are published (different treatments thought to be better) transferability of results to
persons who today undergo screening (compared to no screening) is questionable. This transferability
dilemma is inherent in cancer screening due to the rather long time horizon necessary to assess the effects
of screening (and the subsequent interventions).
With all these complications in evaluating cancer screenings, it is surprising that Professor Miettinen
argues that it should be possible to validly estimate the reduction in the cancer’s case-fatality rate resulting
from screening and earlier treatment for cases that would have become clinically manifest. This calls for a
very special case of comparing two potential outcomes (Little and Rubin, 2000), namely for a person who
would certainly have progressed to clinical disease when undergoing screening (with all the subsequent
cascade of interventions) to a situation with the same person not having been screened. The main difficulty is
that it seems impossible to determine at the time of screening whether the screened person belongs to those
who would have progressed to clinical disease in the absence of screening. Furthermore, it illustrates an
important aspect related to overdiagnosis. If the person (to be screened) has a substantial risk of dying from
another disease, (s)he will have a low probability to have a clinically diagnosed cancer. This form of
overdiagnosis is inevitable (Marcus et al. 2015) and a crucial reason to not recommend screening in older
persons or persons with a reduced life expectancy (for example of less than 10 years).
To conclude themethodological arguments: As much as it would be interesting to knowwhether and by how
much cancer screening is reducing “the cancer’s case-fatality rate resulting from its early treatments following its
early – latent-stage, preclinical – diagnoses in lieu of treatments of the cancer when it already is clinically
manifest” it is an elusive metric which by no study design, even if ideally conducted, can be validly estimated.
As Professor Miettinen illustrates referring to the report on mammography screening prepared by the
Swiss Medical Board (SMB), there are other issues to be addressed such as the composition of expert
groups. Such groups generally should include multidisciplinary knowledge, especially competent experts
with an epidemiological and methodological background as well as competent clinical experts, who have a
broad view and the ability to not only defend their own discipline, knowledge of medical but also of public
health aspects. Special knowledge and experience in evaluating screening interventions is necessary. The
criteria for selection of the evaluation committee are somewhat different to those for the evaluation of
relatively straightforward medical procedures because long-term interventions with a public health focus
like mammography screening with an effect expected only after years or even decades, require special
methodological considerations. Although these thoughts on the composition of such groups are not really
groundbreaking, a careful selection has not been the case for that report (and the reports published earlier
by the SMB). This resulted – not surprisingly – in methodological flaws of the report (de Koning and
Heijnsdijk, 2015) and somewhat incoherent conclusions which might even contradict themselves. By
omitting a discussion of pros and cons of opportunistic mammographies outside of organized programs,
the SMB indirectly supported the opportunistic approach which has no quality assessment at all.
Fortunately, the institution recognized weaknesses, and both the composition of the board and the
processes are being adapted. Unfortunately, the report has never been revised.
What was the aftermath of this report in Switzerland? Mostly confusion and irritation of physicians,
politicians and especially of women. Some regional mammography screening programs in Switzerland may
report lower participation rates after publication of the report, and some cantons (comparable to states in
the USA) have postponed the introduction of mammography screening programs whereas others initiated
their program despite the SMB report. Whether a decline in the participation rate will persist, remains to be
seen. An analysis of other reports published by the SMB showed that such declines – if they occurred – did
not last for a long period of time (Eichler et al. 2015).
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We do agree with exponents of the SMB that irritation per se might not be detrimental, but in all
likelihood a necessary step in the evaluation of interventions. But we believe that in this specific case it was
not necessary but rather counterproductive – the SMB report is based on the information, available for
years now, from the well-known randomized controlled trials, and on a questionable cost-effectiveness-
analysis done by the SMB. Interestingly, the UK panel based its conclusion – that mammography screening
programs confer significant benefit and should continue – on the same trials and their own experience with
decades of mammography screening (Independent UK Panel, 2012). What the SMB report did not lead to is
the abandonment of mammography screening programs in Switzerland.
Interpretation of study results and evaluation of interventions is not always straightforward. It starts
with the question: What kind of evidence should be considered? Only the evidence from randomized
controlled trials (if available), or from observational studies as well? Which models should be used and
which assumptions should be made? The approach chosen will undoubtedly impact on the results and
conclusions, as will the choice of outcome measure, of statistical analysis etc. But even with the same
evidence base, different persons or organizations might come to different conclusions. Ultimately, one has
to weigh positive effects against negative ones – and this is up to a certain degree a question of personal
preferences and may also be subject to change over time. Coming back to mammography screening and the
SMB report, the only positive outcome considered was reduction in breast cancer mortality. As every
clinician taking care of women with breast cancer knows, dying from breast cancer is not the only thing
women would like to prevent. Avoiding more advanced or even late-stage disease by diagnosing breast
cancer early is also a positive outcome for many women. And we should keep in mind that many women
are confronted with breast cancer and its sequels as many families know someone affected by breast cancer
within the family or among their friends.
As discussed above, an RCT in mammography screening evaluating the case-fatality rate, taking into
account overdiagnosis, as proposed by Professor Miettinen, in our opinion would be welcome but is not
feasible. RCTs evaluating breast cancer mortality rate would hardly be feasible, in particular (low) accrual
and selection bias could be a problem nowadays. Nevertheless, results would be available after years
only, and even in properly performed RCTs, generalizability of results will probably be low due to
advances in diagnostics and treatment occurring in the meantime. The priority for new studies should
be on interventions to reduce harms of mammography screening (including diagnostic workup and
treatment), i.e. reducing false positive results and especially reducing overdiagnoses and overtreatment.
Quality for breast cancer screening can best – some would say only – be assured if the screening is
embedded in organized programs, where quality measurement and measures will help further reduce
false positives and negatives. Organized mammography screening programs therefore clearly should be
favored over opportunistic mammographies. Furthermore, trials should be conducted which evaluate less
invasive treatments for potentially indolent disease, especially small size, low grade DCIS and luminal
A invasive cancers. There are indications that e.g. radiation and/or systemic adjuvant therapy can safely
be omitted in certain cases (e.g. McCormick et al. 2015; Christiansen et al. 2011). What we also should
think about is leaving the one-for-all approach and evaluating risk-stratified screening, meaning e.g. no
screening or larger screening intervals for women with low risk for breast cancer and shorter intervals for
women with higher risk. Both these approaches could help reducing overdiagnosis and overtreatment.
We also expect improvements due to technological advances (e.g. tomosynthesis), but we have to make
sure that these will not primarily lead to more diagnoses of even more low-risk (pre-) disease. Risk-
adapted mammography screening based on age, breast-density, BMI, family history and molecular
markers is investigated in the UK (Warwick et al. 2014).
Finally, we need to better understand how to optimally inform the target population about breast
cancer screening and cancer screening in general. Several studies show that there is room for improvement
in this area (e.g. Domenighetti et al. 2003; Hersch et al. 2015). We need to know more on how the
information should be provided and on how women want to be informed about pros and cons of
mammography screening. The aim should be to enable women to make an informed decision on whether
or not to participate in mammography screening programs.
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Finally, we ask researchers in the field to report study results with caution. Interpretation of results is
necessary, but the inherent uncertainty in all results should also be discussed in a balanced way. When
publishing and discussing study results, researchers should also think about the potential consequences for
the lay public – in the sense of Quidquid agis, prudenter agas et respice finem! or in English: Whatever you
do, do it wisely and consider the end.
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